

Anaerobe Cumulative Antibiogram	Antimicrobial Agent						
	Ampicillin/sulbactam	Cefoxitin	Clindamycin	Meropenem	Metronidazole	Moxifloxacin	Piperacillin/tazobactam
<i>Bacteroides fragilis</i>	84	100	26	93	100	61	96
<i>Prevotella species</i>	97	—	69	98	99	66	100
<i>Fusobacterium species</i>	100	—	77	100	95	68	96
Anaerobic gram-positive cocci	—	—	97	100	100	72	99
<i>Propionibacterium acnes</i>	—	—	53	-	0	95	100
<i>Clostridium perfringens</i>	100	—	83	100	100	83	100
<i>Clostridium species (not perfringens)</i>	—	—	67	100	100	62	94

Reference:  
CLSI M100 33rd edition  
Isolates collected from selected US hospitals from Jan. 1, 2013, to  
Dec. 31, 2016.

## Common Indications for Empiric Vancomycin

### Febrile Neutropenia

- High risk (refer to NCCN or IDSA guidelines for criteria) with severe cephalosporin allergy
- Suspected serious catheter-related infection, SSTI, pneumonia, hemodynamic instability, blood culture with gram-positive cocci, or previous MRSA infection/colonization

### Community-Acquired Pneumonia (CAP)

- Severe CAP (ie: admitted to ICU) PLUS hospitalized with IV antibiotics within prior 90 days
- Prior respiratory isolation of MRSA

### Hospital-acquired (HAP)/ventilator-associated (VAP) Pneumonia

- Prior respiratory isolation of MRSA
- Empyema
- Risk factors for resistance or mortality
  - HAP: mechanical ventilation, septic shock, IV antibiotics within 90 days
  - VAP: acute respiratory distress syndrome prior to VAP, septic shock at time of VAP, IV antibiotics within 90 days, acute renal replacement therapy prior to VAP, ≥ 5 days in hospital prior to VAP

### Skin and Soft Tissue Infection (SSTI)

- Severe purulent infection or presence of abscess
- Non-purulent infection with one of the following:
  - Severe cephalosporin allergy
  - MRSA risk (penetrating trauma, MRSA infection elsewhere or nasal colonization, injection drug use, severely immunocompromised)
  - Necrotizing fasciitis
  - ICU admission for SSTI

### Diabetic Foot Infection (DFI)/Chronic Wound

- Any indications listed within SSTI section
- Severe or chronic-moderate
  - Moderate: deeper than skin & subcutaneous tissues, no signs of systemic inflammatory response syndrome (SIRS)
  - Severe: SIRS OR presence of ischemia
- ICU admission for DFI or chronic wound

Scan QR Code  
for a full list of  
indications



## SMH Levofloxacin Guidelines for Use

- CAP when B-lactam allergy present
- HAP/VAP: As 2nd agent if dual pseudomonas coverage indicated
- Acute exacerbation of COPD
- MDR organism
- Pseudomonas if po agent needed
- UTI when B-lactam allergy present (acute uncomplicated cystitis in women)
- UTI if complicated/male
- Prostatitis
- Pyelonephritis step-down
- Gram-negative (excluding pseudomonas) bacteremia step-down if po agent needed
- Intra-abdominal infection
- Uncomplicated febrile neutropenia
- Leukemia antibiotic prophylaxis
- Surgical prophylaxis if B-lactam allergy

2023

# Antimicrobial Agent Susceptibilities

PROVIDED BY

**Microbiology**  
217-788-3057

**Pharmacy**  
217-788-3010



701 N. First St. • Springfield, IL 62781

**Percent Susceptible – All Inpatients**

Jan. 1–Dec. 31, 2022 Inpatient isolates only, first isolate per patient	# Isolates	Percent Susceptible																			
		Ampicillin (\$-IV) (\$-PO)	Ampicillin/subbactam (\$\$)	Cefepime (\$\$)	Ceftazidime (\$\$)	Ceftriaxone (\$)	Clindamycin (\$\$-IV) (c-PO)	Erythromycin (\$\$)	Gentamicin (\$\$)	Levofloxacin (\$-IV) (c-PO)	Linezolid (\$\$-IV) (\$-PO)	Meropenem (\$\$)	Nitrofurantoin (\$)	Oxacillin (\$\$\$)	Penicillin-G (\$\$-IV) (c-PO)	Piperacillin/tazobactam (\$\$)	Tetracycline	TMP/SMX (\$\$\$-IV) (c-PO)	Tobramycin (\$)	Vancomycin (\$\$)	
<b>GRAM-NEGATIVE BACILLI</b>	<b>Percent Susceptible</b>																				
<i>Escherichia coli</i>	876	55	66	100		90	R		95	80			97	R	R	96		95	95	R	
<i>Klebsiella pneumoniae</i>	319	R	83	100		93	R		97	97			31	R	R	97		92	96	R	
<i>Klebsiella oxytoca</i>	82	R	67	100		94	R		100	99			93	R	R	94		98	100	R	
<i>Proteus mirabilis</i>	183	81	95	100		97	R		96	76			R	R	R	100	R	81	96	R	
<i>Enterobacter cloacae</i>	147	R	R	97		76	R		100	99			66	R	R	81		93	100	R	
<i>Enterobacter aerogenes</i>	59	R	R	100		71	R		100	97			17	R	R	86		100	100	R	
<i>Serratia marcescens</i>	60	R	R	100		98	R		100	98			R	R	R			100	90	R	
<i>Citrobacter freundii</i>	44	R	R	100		80	R		98	91			90	R	R	97		89	98	R	
<i>Morganella morganii</i>	33	R	R	96		82	R		88	82			R	R	R	100		67	97	R	
<i>Pseudomonas aeruginosa</i>	336	R	R	93	93	R	R			89		94		R	R	88	R	R	97	R	
<i>Acinetobacter baumannii</i>	53	R	87		72		R		89	74		74		R	R	60		87	89	R	
<i>Stenotrophomonas maltophilia</i>	45	R	R			R	R		R	84		R		R	R	R		96	R	R	
<b>GRAM-POSITIVE COCCI</b>	<b>Percent Susceptible</b>																				
<i>Staphylococcus aureus</i> §	591	R					68	41						56	0			90	98		100
<i>Staphylococcus aureus</i> (MRSA)	275	R					60	17						0	0			85	96		100
<i>Staphylococcus aureus</i> (MSSA)	337	R					74	62						100	0			92	99		100
<i>Staphylococcus epidermidis</i>	132	R					54	31						36	0			79			100
<i>Staphylococcus lugdunensis</i>	27	R					77	77						73	0			96			100
<i>Enterococcus faecalis</i> *	317	100			R	R	R	R											R	R	96
<i>Enterococcus faecium</i> *	66	8			R	R	R	R				100							R	R	14
<i>Streptococcus agalactiae</i> *	24																				100
<i>Streptococcus pyogenes</i> **	23																				100
<i>Streptococcus pneumoniae</i>	33						67 <sup>†</sup>														36 <sup>†</sup>
							94 <sup>‡</sup>		36												94 <sup>‡</sup>

**Percent Susceptible – ICU**

Jan. 1–Dec. 31, 2022 ICU isolates only, first isolate per patient	Isolates	Percent Susceptible																								
		Ampicillin	Ampicillin/subbactam	Cefepime	Ceftazidime	Ceftriaxone	Clindamycin	Erythromycin	Gentamicin	Levofloxacin	Meropenem	Nitrofurantoin	Oxacillin	Penicillin-G	Piperacillin/tazobactam	Tetracycline	TMP/SMX	Tobramycin	Vancomycin							
<b>GRAM-NEGATIVE BACILLI</b>	<b>Percent Susceptible</b>																									
<i>Escherichia coli</i>	117	58	68	100	93	91	R		98	80	100	98	R	R	99		85	97	R							
<i>Klebsiella pneumoniae</i>	59	R	88	100	98	98	R		98	97	100	32	R	R	96		96	98	R							
<i>Proteus mirabilis</i>	29	76	90	100	97	97	R		90	68	100	R	R	R	100	R	62	86	R							
<i>Enterobacter cloacae</i>	30	R	R	96	80	80	R		100	100	100	60	R	R	85		93	100	R							
<i>Pseudomonas aeruginosa</i>	68	R	R	79	82	R	R			84	88		R	R	74	R	R	96	R							
<i>Acinetobacter baumannii</i>	15	R	80	67	67	R	R		93	67	67		R	R	53		93	93	R							
<b>GRAM-POSITIVE COCCI</b>	<b>Percent Susceptible</b>																									
<i>Staphylococcus aureus</i> §	116	R												64	37					49	0		97	98		99

**KEY**

- \* Sterile sites only
- \*\* Combined isolates from 2020–2022
- R Intrinsic resistance
- § First staphylococcus aureus isolate per patient
- † Meningitis interpretations
- ‡ Non-meningitis interpretations

**COST**

- ¢ < \$1
- \$ = \$1–\$10
- \$\$ = \$10–\$50
- \$\$\$ = \$50–\$100
- \$\$\$\$ = \$100–\$200
- \$\$\$\$\$ > \$200